Article

FDA Holds Muscular Dystrophy Trial

Author(s):

Enrollment and dosing in IGNITE DMD has been indefinitely discontinued.

The U.S. Food and Drug Administration (FDA) has placed a Clinical Hold on the IGNITE DMD Phase 2/3 trial for SGT-001 microdystrophin gene transfer in Duchenne muscular dystrophy (DMD), Solid Biosciences Inc. has announced.

IGNITE DMD, which is designed to assess the safety and efficacy of SGT-001 in ambulatory and non-ambulatory children and adolescents with DMD, was stopped after the first patient dosed was hospitalized due to laboratory findings that included a decrease in platelet count followed by a reduction in red blood cell count and evidence of complement activation.

Solid reported the incident to the FDA and it was immediately classified as a Suspected Unexpected Serious Adverse Reaction (SUSAR) because it was not premeditated or anticipated.

For more information, please visit RareDR.com.

Related Videos
Abstract DNA molecule helix inside red blood drop
Woman experiencing pain related to recurrent pericarditis -- Image credit: Art_Photo | stock.adobe.com